SN2DNA | In silico design and assessment of novel polyelectrophylic chemotherapy agents

Summary
Administration of DNA-damaging reagents constitutes one of the most effective chemotherapeutic strategies for the cancer treatment. The families of drugs developed over the years for this purpose are based on second-order nucleophilic substitution (SN2) reactions. Innovative candidates to improve the therapeutic action of these compounds have been designed based on increasing the number of electrophilic positions (En) of the reagent by making n>2. This increased electrophilicity must generate interstrand crosslink adducts that should result in irreversible lesions in the DNA of cancer cells. Computational chemistry tools based on quantum mechanics and molecular modelling, constitute key tools for a better understanding of DNA damage and repair after the formation of the covalently bound complexes that distort the double helix. Thus, the aim of the project described in this proposal is to: 1) compute the structures and evaluate the distorting effects of DNA adducts with polyelectrophilic chemotherapeutic reagents, 2) compute the kinetics of the consecutive SN2 processes (on both carbon atoms and metallic centres) involving interstrand and intrastrand crosslinks and 3) assess in silico the ADME (Adsorption, Distribution, Metabolism and Excretion) properties of the synthesised candidates. Those objectives will be achieved by computing the behaviour of different families of molecules through quantum mechanical - at DFT level of theory- and Molecular Mechanics calculations - based on QM/MM method. Some of these candidates have been synthesised in the laboratories of the hosting group and the corresponding preliminary and promising biological results are already available. The outputs of this project will result in a patent proposal and research articles to be published in high impact journals. Our findings will be open-access available in order to contribute with the research on anticancer drugs design.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101026616
Start date: 01-06-2021
End date: 31-05-2024
Total budget - Public funding: 259 398,72 Euro - 259 398,00 Euro
Cordis data

Original description

Administration of DNA-damaging reagents constitutes one of the most effective chemotherapeutic strategies for the cancer treatment. The families of drugs developed over the years for this purpose are based on second-order nucleophilic substitution (SN2) reactions. Innovative candidates to improve the therapeutic action of these compounds have been designed based on increasing the number of electrophilic positions (En) of the reagent by making n>2. This increased electrophilicity must generate interstrand crosslink adducts that should result in irreversible lesions in the DNA of cancer cells. Computational chemistry tools based on quantum mechanics and molecular modelling, constitute key tools for a better understanding of DNA damage and repair after the formation of the covalently bound complexes that distort the double helix. Thus, the aim of the project described in this proposal is to: 1) compute the structures and evaluate the distorting effects of DNA adducts with polyelectrophilic chemotherapeutic reagents, 2) compute the kinetics of the consecutive SN2 processes (on both carbon atoms and metallic centres) involving interstrand and intrastrand crosslinks and 3) assess in silico the ADME (Adsorption, Distribution, Metabolism and Excretion) properties of the synthesised candidates. Those objectives will be achieved by computing the behaviour of different families of molecules through quantum mechanical - at DFT level of theory- and Molecular Mechanics calculations - based on QM/MM method. Some of these candidates have been synthesised in the laboratories of the hosting group and the corresponding preliminary and promising biological results are already available. The outputs of this project will result in a patent proposal and research articles to be published in high impact journals. Our findings will be open-access available in order to contribute with the research on anticancer drugs design.

Status

CLOSED

Call topic

MSCA-IF-2020

Update Date

28-04-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.1. EXCELLENT SCIENCE
H2020-EU.1.3. EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions (MSCA)
H2020-EU.1.3.2. Nurturing excellence by means of cross-border and cross-sector mobility
H2020-MSCA-IF-2020
MSCA-IF-2020 Individual Fellowships